Harmony Biosciences Holdings, I (HRMY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.50
- Estimate
- $1.15
- Surprise
- +30.6%
- Revenue (period 2026-06-30)
- $261.3M
- Score at report (before → after)
- 7.0 → 7.0/10
Revenue source: xbrl.
How the report landed
Harmony Biosciences Holdings, I (HRMY) beat the $1.15 estimate with diluted EPS of $1.50 — a large 30.6% upside surprise. TrendMatrix's engine moved from Hold (7.0/10) to Buy (Wait) at 7.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HRMY Hold at 7.2/10.
2 of the last 4 quarters beat the estimate; this quarter's +30.6% surprise compares with a -1.6% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: WAKIX
- Concentration risk — Supplier: sole-source suppliers and manufacturers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $41.10
- Price target
- $41.21
- Stop
- $38.56
- Upside to target
- +0.3%
- Reward-to-risk
- 0.0:1
The stock trades at 13.5× trailing but 6.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-11 — shown for context, not personalized investment advice.
HRMY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.39B
- P/E (fwd)
- 6.1
- P/E (ttm)
- 13.5
- 52-week range
- $25.52–$43.49
- Off 52-week high
- 5.5%
- RSI (14)
- 68
- Volume vs avg
- 1.00×
- Score today
- 7.2/10